Iconovo (ICO.ST) Osake Kurssi

Iconovo AB generates revenue through the development, manufacturing, and supply of inhalation products. The company offers device platforms including ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices, and ICOpre, which are part of its device family. Iconovo also provides development programs for generic inhalation products based on therapeutic equivalence, as well as development for inhalation products using generic API and new chemical entity (NCE) applications. These services are targeted at pharmaceutical companies seeking to develop inhalation therapies, particularly for generic and innovative drug delivery systems. The company’s solutions include formulation, analytical testing, and documentation services tied to its device platforms. Iconovo AB’s product portfolio supports the development of pre-metered devices like ICOpre and capsule-based devices such as ICOcap, which are used in respiratory treatment applications. Its clinical trial programs, such as phase I-II trials using ICOone, cater to pharmaceutical clients requiring early-stage development support for inhalation products. Iconovo AB’s business model focuses on providing end-to-end solutions for inhalation product development, from formulation to clinical trials. The company serves pharmaceutical manufacturers who need to bring inhalation therapies to market, leveraging its device platforms and development expertise. Its offerings are structured around specific device types and development pathways, ensuring tailored support for both generic and novel inhalation product launches.